Loading stock data…
Monte Rosa Therapeutics, Inc. (GLUE)
$14.18+0.34 (+2.46%)
Market OpenUpdated 3:55 PM EDT
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Monte Rosa Therapeutics, Inc. in the Healthcare sector is trading at $14.18 with a market capitalization of $1.5B. Wall Street consensus targets $28.50 (6 analysts), implying a +101.0% move over the next 12 months. The stock is currently 45% below its 52-week high of $25.77, remaining 23.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +101.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.97M↑ | $4.21M↑ | $2.78M↓ | $12.77M↓ | $23.19M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$49.13M↑ | -$50.03M↓ | -$49.72M↓ | -$32.98M↓ | -$15.55M |
| Net Income | -$43.40M↑ | -$44.50M↑ | -$46.13M↓ | -$27.08M↓ | -$12.29M |
Peer Comparison
JNJUNHPFE
Fundamentals
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The comp...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.50B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-24.91%
Volume
Today's trading volume
883,512
Recent News
Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon
All three major US stock indexes fell in late-morning trading Tuesday as oil prices climbed and inve
Monte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal
Monte Rosa Therapeutics, Inc. recently reported second-quarter 2026 results showing a net loss of US$43.4 million, up from US$12.3 million a year earlier, with basic and diluted loss per share widening to US$0.43 from US$0.15. For the first half of 2026, the company swung from net income of US$34.59 million to a net loss of US$87.9 million, marking a sharp reversal in its earnings profile. Next, we’ll examine how this sharp widening of losses shapes Monte Rosa Therapeutics’ investment...
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -72.00% and -65.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
BIOA clocked its worst day since December 2024 on Friday, while GLUE booked its worst day ever.
Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial
Novo Nordisk (NVO) shares tumbled Friday after the Danish pharmaceutical giant said a late-stage tri